Mankind Pharma reported strong second-quarter results for FY2026–27, with consolidated profit after tax (PAT) increasing 37.7% year on year to ₹716 crore. Revenue from operations rose 17.3% to ₹4,338 crore for the quarter ended September 30, 2026, as demand for chronic and acute medicines supported domestic growth and international operations expanded.
The pharmaceutical company also improved its operating profitability, with earnings before interest, tax, depreciation and amortisation (EBITDA) rising 27.2% to ₹1,175 crore. Its EBITDA margin expanded by 210 basis points to 27.1%, indicating that operating earnings grew faster than revenue. However, consumer healthcare growth remained subdued, highlighting differences in performance across the company’s business segments.
Key Takeaways
- PAT: Increased 37.7% to ₹716 crore from approximately ₹520 crore a year earlier.
- Revenue: Rose 17.3% to ₹4,338 crore in Q2 FY27.
- EBITDA: Grew 27.2% to ₹1,175 crore.
- Operating margin: Expanded 210 basis points to 27.1%.
- Domestic pharmaceutical business: Revenue excluding consumer healthcare increased 15.9% to ₹3,428 crore.
- Exports: Rose 32.7% to ₹681 crore.
- Consumer healthcare: Revenue grew just 1.2% to ₹229 crore.
- Strategic expansion: The acquisition of Armed Cell Therapeutics marks Mankind Pharma’s entry into next-generation CAR-T therapies.
Mankind Pharma Q2 FY27 Results at a Glance
The September-quarter results show growth across the company’s principal financial indicators, with profit increasing faster than sales.
| Financial metric | Q2 FY27 | Q2 FY26 | YoY growth |
|---|---|---|---|
| Revenue from operations | ₹4,338 crore | ₹3,697 crore | 17.3% |
| EBITDA | ₹1,175 crore | ₹924 crore | 27.2% |
| Profit after tax (PAT) | ₹716 crore | ₹520 crore | 37.7% |
| EBITDA margin | 27.1% | 25.0% | +210 bps |
| PAT margin | 16.5% | 14.1% | +240 bps |
Figures are rounded. Growth rates and margins are based on company-reported figures. Sources: Fortune India and Business Standard.
The expansion in both EBITDA and PAT margins suggests that the company converted a greater share of its revenue into operating earnings and net profit. However, one quarter alone does not establish whether the improved margins will continue.
Domestic Pharmaceutical Business Drives Growth
Mankind Pharma’s domestic pharmaceutical business remained a key contributor to the quarter’s performance. Revenue from the domestic business excluding consumer healthcare increased 15.9% year on year to ₹3,428 crore.
The company said its domestic business outperformed the Indian Pharmaceutical Market on a volume basis. Demand for medicines used to manage long-term conditions, including cardiovascular disease and diabetes, supported the performance.
The chronic therapy portfolio recorded strong growth in cardiac and anti-diabetes treatments. The company’s acute therapy portfolio also expanded, supported by gastroenterology and vitamins, minerals and nutrition products.
| Domestic therapy segment | Reported growth |
|---|---|
| Cardiac therapies | 19% |
| Anti-diabetes therapies | 16% |
| Gastroenterology | 19% |
| Vitamins, minerals and nutrition | 26% |
Growth rates are rounded from company-reported figures.
Chronic therapies are particularly important for pharmaceutical companies because many patients require ongoing treatment. Strong demand in these categories can help support recurring sales, although prescription volumes, competition, pricing and product mix continue to influence results.
Mankind Pharma’s domestic performance also reflects the importance of its broad medicine portfolio. Growth across both chronic and acute therapies reduces reliance on a single treatment category.
International Business and Exports Expand
International operations provided another source of growth during the quarter. Exports increased 32.7% year on year to ₹681 crore, supported by the international businesses of Mankind Pharma and Bharat Serums and Vaccines (BSV).
The company also launched one new product in the United States, taking the total number of products it had launched in that market to 50.
International expansion can provide pharmaceutical companies with additional revenue opportunities, but overseas markets also involve regulatory requirements, product approvals, distribution costs and competition. Sustaining growth will depend on how effectively Mankind expands its product portfolio and commercial presence.
The contribution from BSV is also strategically relevant because the business operates in specialty pharmaceuticals and biological therapies. Its performance can help Mankind broaden its portfolio beyond its traditional domestic medicines business.
Consumer Healthcare Growth Remains Muted
Consumer healthcare was a weaker area in the September quarter. Revenue increased 1.2% year on year to ₹229 crore, as the company faced slower category demand and regional weakness in eastern and southern India.
The segment includes consumer-facing brands, where sales can be influenced by retail distribution, brand awareness, online channels and household spending patterns.
Despite slower overall growth, Mankind reported gains in modern trade and e-commerce. These channels accounted for 18% of consumer healthcare revenue in Q2 FY27, compared with 12% in the year-ago quarter. The company reported 55% growth in these channels.
The figures suggest that digital and organized retail distribution is becoming more important to the business. However, stronger performance in these channels has not yet translated into comparable growth across the entire consumer healthcare segment.
Mankind Pharma’s First-Half FY27 Performance
The company also reported growth for the first six months of FY27, indicating that the second-quarter performance forms part of a broader expansion in revenue and profitability.
| Financial metric | H1 FY27 | Year-on-year growth |
|---|---|---|
| Revenue from operations | ₹8,368 crore | 15.1% |
| EBITDA | ₹2,235 crore | 26.0% |
| Profit after tax | ₹1,290 crore | 33.7% |
| EBITDA margin | 26.7% | +230 bps |
The first-half figures show that EBITDA and net profit grew considerably faster than revenue. This indicates improved profitability across the period, although investors will need to assess whether the trend is sustainable in subsequent quarters.
The results also give investors a broader view of the company’s performance beyond a single reporting period. Consistent revenue growth, stable margins and cash generation will remain important measures of financial quality.
Armed Cell Therapeutics Acquisition Adds a New Growth Avenue
Mankind Pharma’s acquisition of Armed Cell Therapeutics marks a strategic move into next-generation CAR-T therapies.
CAR-T, or chimeric antigen receptor T-cell therapy, is a form of treatment that modifies a patient’s immune cells to recognize and attack cancer cells. These therapies represent a specialized area of medicine and require significant scientific, manufacturing and regulatory capabilities.
The acquisition gives Mankind a route to develop capabilities in a more advanced segment of healthcare. It could broaden the company’s long-term research and development opportunities beyond its existing portfolio.
However, the strategic value of the acquisition will depend on future development milestones, regulatory progress, commercialization and the resources required to build the business. The transaction should therefore be viewed as a longer-term growth initiative rather than an immediate explanation for the quarter’s earnings increase.
The Bigger Picture
Mankind Pharma’s Q2 FY27 results reflect a combination of strong domestic pharmaceutical demand, international expansion and improved operating profitability. Revenue increased at a healthy double-digit pace, while profit growth outstripped sales growth. The performance of chronic therapies is particularly notable because long-term treatment categories can support recurring demand.
The results also show why segment-level analysis matters. Consumer healthcare grew only marginally, even as prescription medicines and exports performed more strongly. Meanwhile, the move into CAR-T therapies signals an ambition to expand into specialized treatments. For investors, the key questions will be whether margins remain elevated, international growth continues and the company’s newer investments generate sustainable returns.
FAQs
1. What was Mankind Pharma’s Q2 FY27 net profit?
Mankind Pharma reported consolidated profit after tax of approximately ₹716 crore for Q2 FY27, up 37.7% from around ₹520 crore in Q2 FY26.
2. How much did Mankind Pharma’s revenue grow in Q2 FY27?
Revenue from operations increased 17.3% year on year to ₹4,338 crore for the quarter ended September 30, 2026.
3. What was Mankind Pharma’s EBITDA margin in Q2 FY27?
The company’s EBITDA margin increased to 27.1%, compared with 25.0% in the corresponding quarter of the previous year, an improvement of 210 basis points.
4. Which business segments drove Mankind Pharma’s growth?
The domestic pharmaceutical business and international operations were important contributors. Demand for cardiac, anti-diabetes, gastroenterology and nutrition-related therapies supported domestic performance, while exports rose 32.7%.
5. Is Mankind Pharma a buy after its Q2 results?
Strong earnings growth can be a positive signal, but it does not by itself determine whether a stock is attractively valued. Investors should also assess valuation, future earnings expectations, debt, cash flow, competitive risks and their own investment objectives. This article does not constitute investment advice.
Looking Ahead
Mankind Pharma’s near-term performance will depend on continued demand across its domestic medicine portfolio, the expansion of international operations and its ability to sustain improved margins. Investors will also watch whether consumer healthcare growth improves and whether the company can maintain its momentum in chronic therapies.
Over the longer term, the Armed Cell Therapeutics acquisition could broaden Mankind’s presence in advanced therapies, but its contribution will depend on development and commercialization progress. The company’s next results will help clarify whether the strong first-half performance can continue into the remainder of FY27.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
